The estimated Net Worth of Jason Gardner is at least $3.65 Миллион dollars as of 16 September 2021. Mr. Gardner owns over 14,340 units of Magenta Therapeutics Inc stock worth over $200,810 and over the last 6 years he sold MGTA stock worth over $1,794,131. In addition, he makes $1,651,000 as President, Chief Executive Officer, Co-Founder и Director at Magenta Therapeutics Inc.
Sign up
Mr. Gardner MGTA stock SEC Form 4 insiders trading
Jason has made over 8 trades of the Magenta Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 14,340 units of MGTA stock worth $96,508 on 16 September 2021.
The largest trade he's ever made was selling 76,711 units of Magenta Therapeutics Inc stock on 20 December 2019 worth over $1,162,939. On average, Jason trades about 7,041 units every 66 days since 2018. As of 16 September 2021 he still owns at least 286,872 units of Magenta Therapeutics Inc stock.
You can see the complete history of Mr. Gardner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jason Gardner biography
Jason Gardner is a President, Chief Executive Officer, Co-Founder, Director of the Company. Dr. Gardner has more than 20 years of experience in stem cell science, drug development and industry leadership roles. He joined Atlas Venture in November 2015 as an Entrepreneur-in-Residence to create Magenta with Third Rock Ventures. He previously worked at GlaxoSmithKline plc. from 2005, most recently as Vice President and Head of the R&D Satellite in Boston. He created and led the Regenerative Medicine Unit, established partnerships with The Harvard Stem Cell Institute, and The Telethon Institute for Gene Therapy, from which the first stem cell gene therapy (Strimvelis) was approved. Prior to that, Dr. Gardner was the Head of the Center of Excellence for External Drug Discovery and was a member of the clinical project team that led the late stage development and NDA approval for Tykerb for breast cancer. Dr. Gardner held scientific leadership roles at Progenics Pharmaceuticals, Inc. and Chiron Corporation working on drug discovery and development. Dr. Gardner completed a postdoctoral fellowship in stem cell biology with Professor David Scadden at Harvard Medical School
What is the salary of Jason Gardner?
As the President, Chief Executive Officer, Co-Founder и Director of Magenta Therapeutics Inc, the total compensation of Jason Gardner at Magenta Therapeutics Inc is $1,651,000. There are 1 executives at Magenta Therapeutics Inc getting paid more, with Christina Isacson having the highest compensation of $2,277,560.
How old is Jason Gardner?
Jason Gardner is 49, he's been the President, Chief Executive Officer, Co-Founder и Director of Magenta Therapeutics Inc since 2016. There are 12 older and 8 younger executives at Magenta Therapeutics Inc. The oldest executive at Magenta Therapeutics Inc is David Scadden, 67, who is the Independent Director.
What's Jason Gardner's mailing address?
Jason's mailing address filed with the SEC is C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139.
Insiders trading at Magenta Therapeutics Inc
Over the last 6 years, insiders at Magenta Therapeutics Inc have traded over $6,775,591 worth of Magenta Therapeutics Inc stock and bought 1,257,000 units worth $10,105,000 . The most active insiders traders include Bruce Booth, Rock Ventures Iv, L.P.Third... и Jeffrey W. Albers. On average, Magenta Therapeutics Inc executives and independent directors trade stock every 46 days with the average trade being worth of $99,614. The most recent stock trade was executed by Rock Ventures Iv, L.P.Third... on 7 February 2023, trading 3,700,000 units of MGTA stock currently worth $3,071,000.
What does Magenta Therapeutics Inc do?
magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.
What does Magenta Therapeutics Inc's logo look like?
Complete history of Mr. Gardner stock trades at Magenta Therapeutics Inc
Magenta Therapeutics Inc executives and stock owners
Magenta Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Christina Isacson,
Chief Business Officer -
Jason Gardner,
President, Chief Executive Officer, Co-Founder, Director -
John Davis,
Chief Medical Officer, Head of Research and Development -
Dr. Jason Gardner Ph.D.,
Co-Founder, CEO, Pres & Director -
Stephen F. Mahoney J.D., MBA,
Chief Financial & Operating Officer and Treasurer -
Anne McGeorge,
Independent Director -
David Scadden,
Independent Director -
Michael Bonney,
Independent Chairman of the Board -
Alexis Borisy,
Independent Director -
Jeffrey Albers,
Independent Director -
Thomas Daniel,
Independent Director -
Bruce Booth,
Independent Director -
Blake Byers,
Independent Director -
Amy Ronneberg,
Independent Director -
Steve Mahoney,
Chief Financial and Operating Officer -
Manisha Pai,
Vice President - Communications and Investor Relations -
Zoran Zdraveski,
Secretary and Chief Legal Officer -
Li Malmberg,
Senior Vice President - Head of Manufacturing -
Kristen Stants,
Chief People Officer -
Cindy Driscoll,
Vice President - Finance -
Dr. Jan Pinkas Ph.D.,
Sr. VP & Head of Translational Sciences -
Catherine Monaghan,
Head of Clinical Devel. Operations -
Kristen Stants,
Chief People Officer -
Lyndsey Scull,
Director of Corp. Communications -
Thomas W. Beetham,
Chief Legal Officer -
Jim Haney,
Sr. Director of Investor Relations -
Dr. Lisa M. Olson Ph.D.,
Head of Research & Chief Scientific Officer -
David Wayne Nichols,
Chief Technical Officer -
Lisa Olson,
See Remarks -
Caren Deardorf,
Chief Commercial Officer -
Venture Fund X, L.P.Atlas V...,
-
Rock Ventures Iv, L.P.Third...,
-
2016 Gp, L.L.C.Gv 2016 Gp, ...,
-
Jason Ryan,
See Remarks -
Venture Fund X, L.P. Atlas,
10% owner -
Stephen F. Mahoney,
See Remarks -
Michael P. Cooke,
Chief Scientific Officer -
Thomas W. Beetham,
See Remarks -
Jeffrey Humphrey,
Chief Medical Officer -
Alison Frances Lawton,
Director -
David Wayne Nichols,
Chief Technical Officer -
Michael Vasconcelles,
Director